Vertaling van "bivalent l1 virus-like " (Frans → Nederlands) :

- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757- 1765.
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus

- Paavonen J, Jenkins D, Bosch FX, Naud P, Salméron J, C. Wheeler et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
- Paavonen J, Jenkins D, Bosch FX, Naud P, Salméron J, C. Wheeler et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind, randomised controlled trial.

Au début des années nonante du siècle dernier, on a découvert que les « Virus Like Particles » (VLP) pouvaient être développées en exprimant la protéine L1 de la capsule notamment dans des cellules de levure ou des lignées cellulaires provenant d’insectes.
Begin jaren negentig van vorige eeuw ontdekte men dat zogenaamde “Virus Like Particles” (VLP) ontwikkeld konden worden door expressie van het L1 kapseleiwit in onder meer gistcellen of cellijnen afkomstig van insecten.